支气管哮喘相关基因ADAM33的研究进展

The Research Progress of Gene ADAM33 in the Pathogenesis of Asthma and COPD

支气管哮喘和慢性阻塞性肺疾病均是慢性气道炎症性疾病,尽管从发病机制到临床表现两者各有不同,但越来越多的研究表明两者在病因、发病机制和临床表现等诸多方面均有许多相似之处。解整合素-金属蛋白酶(a disintegrin and metalloprotease,ADAM)33基因作为首次通过定位克隆技术确定的哮喘易感基因,近几年的研究证实该基因与慢性阻塞性肺疾病的发生发展也有关联。ADAM33基因是否能架起哮喘和慢性阻塞性肺疾病共同发病机制的桥梁,笔者对近年来该基因的研究进展进行综述。

Asthma and chronic obstructive pulmonary disease （COPD） are chronic airway inflammatory disease. Although there are many differences from pathogenesis to clinical manifestations between these two diseases, a growing number of studies have shown that both have many similarities in the etiology, pathogenesis and clinical manifestations. In recent years, a disintegrin and metalloprotease 33 （ADAM33） gene, as the first asthma susceptibility gene identified by positional cloning, has been confirmed that are associated with the development and course of COPD, Is ADAM33 gene the bridge of asthma and COPD in pathogenesis？ This review summarized the recent research progress of ADAM33 gene.